LZLieve Mees van Zijverden

Lieve Mees van Zijverden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lieve Mees van Zijverden has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular health in transgender and gender-diverse individuals: an expert opinion on gender-affirming hormone therapy, risk assessment and clinical management

    by Marco Vecchiato, Lieve Mees van Zijverden, Jason van Heesewijk, Alberto Scala, Alessandro Biffi, Elena Campello, Paul Connelly, Andrea Garolla, Sean J Iwamoto, Bethany A Jones, et al.

    Transgender and gender-diverse (TGD) individuals represent a growing population with specific cardiovascular health needs. Current cardiovascular prevention strategies are largely derived from cisgender populations and may not adequately account for the combined effects of gender-affirming hormone therapy (GAHT) and other determinants. This expert opinion summarizes current evidence regarding cardiovascular health in TGD individuals, focusing on the cardiovascular effects of GAHT, population-specific cardiovascular risk factors, practical approaches to cardiovascular risk assessment, and future research priorities. Available evidence indicates that GAHT is associated with changes in cardiometabolic risk factors, haemostasis, vascular function, and cardiac physiology. Feminizing GAHT is associated with an increased risk of venous thromboembolism, whereas masculinizing GAHT is associated with adverse lipid changes, erythrocytosis, and a potentially increased risk of major cardiovascular events. However, causal inference is limited by the predominance of observational studies, relatively young study populations, heterogeneous GAHT regimens, short follow-up, and the absence of randomized study evidence. Population-level cardiovascular disparities in TGD individuals should not be attributed to GAHT alone as smoking, obesity, physical inactivity, minority stress, socioeconomic disadvantage, and unequal access to healthcare may independently or interactively influence cardiovascular risk. Current cardiovascular risk prediction tools have not been validated or calibrated in TGD populations and do not account for GAHT exposure or TGD-specific psychosocial and structural determinants. Cardiovascular risk assessment in TGD individuals should integrate conventional risk factors, transgender-related cardiovascular risk factors, and patient involvement regarding individual goals. A coordinated multidisciplinary approach may facilitate personalized cardiovascular prevention while supporting access to gender-affirming care. Future research should prioritize long-term prospective studies and the development of risk prediction models tailored to TGD populations.

  • Open Access

    Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study

    by Lieve Mees van Zijverden, Abel Thijs, Jeske Joanna Katarina van Diemen, Chantal Maria Wiepjes, Martin Den Heijer

    Background and Aims: Despite favourable effects of oestradiol on cardiovascular risk factors, previous studies found higher risks of cardiovascular events in transgender women using gender-affirming hormone therapy. However, these studies did not adjust for socioeconomic status and lifestyle. This study investigated the association between gender-affirming hormone therapy and cardiovascular event risk in a large cohort of transgender persons compared with the general population, accounting for these factors. Methods: This retrospective cohort study included transgender women and transgender men using gender-affirming hormone therapy between 1972 and 2018 at the Amsterdam gender clinic. Medical diagnoses were registered from 2012 to 2022 by a national data registry. Standardized incidence ratios for myocardial infarction, ischaemic cerebrovascular accident, and venous thromboembolism were computed using general population incidence rates adjusted for socioeconomic status, estimated by education, employment, and income. Lifestyle (body mass index, smoking, and alcohol consumption) was analysed by age group. Results: Adjusted for socioeconomic status, transgender women (N = 2714, 23 907 person-years) had lower myocardial infarction risk (.50 [.32; .71]), similar cerebrovascular accident risk (.94 [.72; 1.19]), and higher venous thromboembolism risk (1.81 [1.33; 2.35]) compared with general population men. Transgender men (N = 1617, 13 457 person-years) had higher myocardial infarction risk (4.20 [2.72; 6.01]), higher cerebrovascular accident risk (1.55 [1.01; 2.20]), and similar venous thromboembolism risk (1.00 [.53; 1.61]) compared with general population women. Socioeconomic status minimally impacted these results. Lifestyle largely resembled the general population. Conclusions: Gender-affirming hormone therapy is not associated with increased cardiovascular risk in transgender women but is in transgender men. This aligns with known effects of oestradiol and testosterone on cardiovascular risk factors.


  • Top Cited Papers
    Open Access

    Cardiovascular disease in transgender people: a systematic review and meta-analysis

    by Lieve Mees van Zijverden, Chantal Maria Wiepjes, Jeske Joanna Katarina van Diemen, Abel Thijs, Martin Den Heijer

    Objective: Hormone therapy in transgender people might be associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate whether the risk of CVD is increased in transgender people compared with people of the same birth sex. Design and methods: PubMed, Cochrane, Embase, and Google Scholar were searched until July 2022. Studies evaluating cardiovascular events in transgender women or men were included. Primary outcomes were stroke, myocardial infarction (MI), and venous thromboembolism (VTE). The risk for transgender women versus cisgender men and for transgender men versus cisgender women was analysed through random-effects meta-analysis. Results: Twenty-two studies involving 19 893 transgender women, 14 840 transgender men, 371 547 cisgender men, and 434 700 cisgender women were included. The meta-analysis included 10 studies (79% of transgender women and 76% of transgender men). In transgender women, incidence of stroke was 1.8%, which is 1.3 (95% confidence interval [CI], 1.0-1.8) times higher than in cisgender men. Incidence of MI was 1.2%, with a pooled relative risk of 1.0 (95% CI, 0.8-1.2). Venous thromboembolism incidence was 1.6%, which is 2.2 (95% CI, 1.1-4.5) times higher. Stroke occurred in 0.8% of transgender men, which is 1.3 (95% CI, 1.0-1.6) times higher compared with cisgender women. Incidence of MI was 0.6%, with a pooled relative risk of 1.7 (95% CI, 0.8-3.6). For VTE, this was 0.7%, being 1.4 (95% CI, 1.0-2.0) times higher. Conclusions: Transgender people have a 40% higher risk of CVD compared with cisgender people of the same birth sex. This emphasizes the importance of cardiovascular risk management. Future studies should assess the potential influence of socio-economic and lifestyle factors.


  • Open Access

    The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial

    by Lieve Mees van Zijverden, Moya Henriëtte Schutte, Milou Cecilia Madsen, Tobias Nicolaas Bonten, Yvo Michiel Smulders, Chantal Maria Wiepjes, Jeske Joanna Katarina van Diemen, Abel Thijs

    Patients with severe infection have an increased risk of cardiovascular events. A possible underlying mechanism is inflammation-induced platelet aggregation. We investigated whether hyperaggregation occurs during infection, and whether aspirin inhibits this. In this multicentre, open-label, randomised controlled trial, patients hospitalised due to acute infection were randomised to receive 10 days of aspirin treatment (80 mg 1dd or 40 mg 2dd) or no intervention (1:1:1 allocation). Measurements were performed during infection (T1; days 1–3), after intervention (T2; day 14) and without infection (T3; day > 90). The primary endpoint was platelet aggregation measured by the Platelet Function Analyzer® closure time (CT), and the secondary outcomes were serum and plasma thromboxane B2 (sTxB2 and pTxB2). Fifty-four patients (28 females) were included between January 2018 and December 2020. CT was 18% (95%CI 6;32) higher at T3 compared with T1 in the control group (n = 16), whereas sTxB2 and pTxB2 did not differ. Aspirin prolonged CT with 100% (95%CI 77; 127) from T1 to T2 in the intervention group (n = 38), while it increased with only 12% (95%CI 1;25) in controls. sTxB2 decreased with 95% (95%CI − 97; − 92) from T1 to T2, while it increased in the control group. pTxB2 was not affected compared with controls. Platelet aggregation is increased during severe infection, and this can be inhibited by aspirin. Optimisation of the treatment regimen may further diminish the persisting pTxB2 levels that point towards remaining platelet activity. This trial was registered on 13 April 2017 at EudraCT (2016-004303-32).